Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Children With Systemic Juvenile Idiopathic Arthritis
NCT04088396Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2020
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 14
01
Overview
A Phase 3 trial of baricitinib in systemic juvenile idiopathic arthritis (SJIA), sponsored by Eli Lilly and Company. Started Feb 2020; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT04088396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088396.